GPCR – structure therapeutics inc. (US:NASDAQ)
Stock Stats
News
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $80.00 price target on the stock.
Structure Therapeutics Inc. (NASDAQ: GPCR) had its "market outperform" rating re-affirmed by analysts at JMP Securities. They now have a $91.00 price target on the stock.
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity [Yahoo! Finance]
Structure Therapeutics Announces Selection of Lead Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
Structure Therapeutics Inc. (NASDAQ: GPCR) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $80.00 price target on the stock.
Form 8-K Structure Therapeutics For: Dec 17
Form SC 13G/A Structure Therapeutics Filed by: RA CAPITAL MANAGEMENT, L.P.
Form SC 13G Structure Therapeutics Filed by: JANUS HENDERSON GROUP PLC
Form SC 13G/A Structure Therapeutics Filed by: Avoro Capital Advisors LLC
Form 10-Q Structure Therapeutics For: Sep 30
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.